

## **TECVAYLI™▼ (teclistamab) Patient Card**

Carry this card with you at all times.  
**SHOW THIS CARD** to any healthcare professional  
involved in your care and if you go to the hospital

FOLD HERE This card has been reviewed and approved by the Saudi Food and Drug Authority (SFDA), Version 2

---

**TECVAYLI (teclistamab) can cause side effects such as Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).<sup>1</sup>**

**PATIENT'S NAME:**

---

FOLD HERE This card has been reviewed and approved by the Saudi Food and Drug Authority (SFDA)

## Important Safety Information for Patients

Get medical help straight away if you experience any of the following:<sup>1</sup>

### Cytokine Release Syndrome (CRS)

- Fever (38°C or higher)
- Chills
- Fast heartbeat
- Difficulty breathing
- Nausea
- Headache
- Feeling dizzy

### Neurologic toxicity, including ICANS

- Feeling confused
- Feeling less alert
- Having difficulty writing
- Having difficulty speaking
- Sleepiness
- Loss of ability to carry out skilled movement and gestures (despite having the physical ability and desire to perform them)

FOLD HERE

This card has been reviewed and approved by the Saudi Food and Drug Authority (SFDA)

**IMPORTANT TO REMEMBER: Stay close to the location where you received your TECVAYLI (teclistamab) therapy for at least 2 days for daily monitoring after administration of your first three doses (usually two step-up doses and first maintenance dose).<sup>1</sup>**

If you have any of the symptoms listed on this card call your doctor or seek emergency medical attention right away! These are not all the possible side effects of TECVAYLI (teclistamab). Tell your doctor if you have any side effect that bothers you or does not go away.

This card has been reviewed and approved by the Saudi Food and Drug Authority (SFDA)

## Treating Physician

TREATING PHYSICIAN'S NAME:

TREATING PHYSICIAN'S PHONE  
NUMBER:

---

---

HOSPITAL NAME AND  
ADDRESS:

PHONE NUMBER:

---

---

FOLD HERE This card has been reviewed and approved by the Saudi Food and Drug Authority (SFDA)

### Information for Healthcare Team to Fill In

Please give this card to your healthcare team to fill in the information and return to you.

Dates of TECVAYLI (teclistamab) injections (step-up dosing schedule):

**STEP-UP DOSE 1**

---

**STEP-UP DOSE 2**

---

**FIRST MAINTENANCE DOSE\***

---

\*This is the first full treatment dose (1.5 mg/kg)<sup>1</sup>

This card has been reviewed and approved by the Saudi Food and Drug Authority (SFDA)

## Important Safety Information for Healthcare Professionals

CRS and neurologic toxicity, including ICANS, may occur in patients receiving TECVAYLI (teclistamab), and can be fatal or life-threatening. The majority of these events observed following administration were Grade 1 and 2.<sup>1</sup>

Assess the patient for signs and symptoms of CRS and ICANS. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's treating physician immediately for further information.

See Summary of Product Characteristics for full details.<sup>1</sup>

This card has been reviewed and approved by the Saudi Food and Drug Authority (SFDA)

FOLD HERE

### Adverse Events Reporting Guidance

The National Pharmacovigilance Center (NPC)

Call Center: 19999

E-mail: [npc.drug@sfda.gov.sa](mailto:npc.drug@sfda.gov.sa)

Website: <https://ade.sfda.gov.sa/>

For full prescribing information, please refer to the datasheet or contact Johnson & Johnson Middle East FZ-LLC (Riyadh)

Address: Prince Muhammed Bin Abdulaziz Rd, Tower B, Level 30, Olaya towers.

Office Tel: 00966-11-4339133, Postal address: P O Box 65305 Riyadh 11556, Saudi Arabia

To report Adverse Events/Product Complaint or any Medical Information Inquiries, please contact us at:

Email: [GCC-PV2@its.inj.com](mailto:GCC-PV2@its.inj.com) Hotline: 00966540015811

1. TECVAYLI Summary of Product Characteristics.

This card has been reviewed and approved by the Saudi Food and Drug Authority (SFDA)

**EM-104491**  
**October 2023**